Sun Pharma is acquiring the remaining 21.52% of Taro Pharma for $347.7 million, gaining full control of the subsidiary. This strategic move strengthens Sun Pharma’s global reach, particularly in the US, and allows for streamlined operations and cost synergies. Analysts see it as value-adding, despite initial investor concerns about the offer price. The acquisition is expected to be completed by March 2025, boosting Sun Pharma’s position in the pharmaceutical market.
About Taro Pharmaceuticals
Taro Pharmaceutical Industries is an Israeli research-based pharmaceutical manufacturer publicly listed in the New York Stock Exchange. The company has more than 180 of its own drugs sold all over the world, reaching the markets of over 25 countries. The company’s products are mainly sold in the United States, Canada and Israel.
Read Further
Tags: Sun Pharma, Taro Pharma, Acquisition, Pharmaceutical Industry, Global Reach, US Market, Cost Synergies, Drug Manufacturing, Global Markets
Leave a Reply
You must be logged in to post a comment.